Home » DEA Medical Marijuana Registration: 900 Dispensaries Approved, Nearly 7,000 Waiting and a November 29 Deadline
DEA registration forms medical marijuana businesses

DEA Medical Marijuana Registration: 900 Dispensaries Approved, Nearly 7,000 Waiting and a November 29 Deadline

Federal cannabis reform in the United States is now moving on two tracks at very different speeds. The legal track, a formal hearing on whether all marijuana should leave Schedule I, finished taking testimony in July, was paused for a month over a government watchdog report, and is now winding down a final round of written arguments. The practical track has moved much faster. The U.S. Drug Enforcement Administration (DEA) opened online registration forms for growers, processors, carriers and testing labs in October, and on October 30 it did something it had never done before: it granted federal registrations to more than 900 state-licensed medical marijuana dispensaries, published a list of 6,983 businesses waiting in line, and told all of them that from November 29 they may trade only with each other.

The new documents sit on the website of the DEA Diversion Control Division, the branch of the agency that registers everyone who legally handles controlled substances. The registrations were announced in a Department of Justice press release on October 30, and the trading rule comes from a four-page DEA document called Timely Applicant Information for Medical Marijuana Applicants, published the same day. Cannabis Business Times, which first described the October registration forms, reported on November 2 that the new rule poses major disruptions to state programs. This article, first published at the start of the hearing and updated in October with the new forms, has been updated again with the first registrations, the November 29 deadline and the judge’s ruling on the hearing.

Key Takeaways

The DEA has issued its first federal registrations under the April rescheduling order: more than 900 medical marijuana dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia, each of which passed a pre-registration investigation. A DEA list published the same day shows 6,983 businesses that applied within the 60-day window that closed on June 26, among them 4,197 dispensaries, 2,076 manufacturers and 710 distributors; Oklahoma alone accounts for 2,442 of them. The agency calls these businesses “Timely Applicants” and lets them keep operating under their state licenses while their applications are pending, but only with each other and with registered companies. From November 29 they may not buy from, sell to or ship through any business that did not apply in time, and doing so can be grounds for denying an application or revoking a registration. Testing labs are the one exception, under narrow conditions. The DEA now has dedicated registration forms for state-licensed manufacturers, distributors and analytical labs, filed through a new version of DEA Form 225 at nonrefundable fees of $3,699, $1,850 and $296 a year, according to Cannabis Business Times; the fee reported for dispensaries is $794. Registration matters because the April order moved only state-licensed medical marijuana and FDA-approved products to Schedule III; everything else stays in Schedule I. The hearing on moving all marijuana to Schedule III is no longer frozen: on October 22 the judge refused to reopen it for new testimony, added the watchdog report to the record and allowed one round of written arguments, with replies due November 5. His recommendation still has no date, and the final decision belongs to the DEA Administrator.

DEA Medical Marijuana Registration: What Changed on October 30

Until the end of October, federal registration of a cannabis business was a promise on paper. Thousands of companies had filed applications in the spring, some had been inspected, but none held a certificate. That changed on October 30, when the Justice Department announced that the DEA was issuing the first batch of registrations to dispensaries that had applied within the initial 60-day window and had passed what the department calls the agency’s established pre-registration investigation. The department describes this as the first phase of implementing the Attorney General’s April 23 order under section 811(d) of the Controlled Substances Act.

The numbers are smaller than the applicant pool suggests. The first round covers more than 900 dispensaries in seven states: Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia. Six of those are states with medical-only programs; Virginia has legalized possession for adults but has no retail adult-use market. States with large dual markets, such as California, Colorado and Michigan, are absent from the first batch. The DOJ release does not explain the choice, though the April order’s requirement that an applicant operate under a state framework consistent with federal law and treaty obligations is the obvious place to look.

Attorney General Todd Blanche framed the registrations as a matter of patient access, saying in the release that regulated distribution by registered applicants would help ensure broader access to chronic pain treatment and the safety of the American people, and that the department would keep prosecuting illegal marijuana trafficking. The release also makes a point that every state licensee should read twice: state licensure alone does not automatically grant federal registration, and registered dispensaries take on federal requirements for security, recordkeeping and inventory controls.

Manufacturers and distributors are further back in the queue. The DOJ says their applications require additional review, including facility inspections, production controls and quota determinations, and that dispensary registrations will continue through a phased process. No manufacturer or distributor registration had been announced at the time of this update.

Who Is Waiting: the DEA’s List of 6,983 Timely Applicants

Alongside the registrations, the DEA published something the industry had been asking for since spring: a public list of every business that applied within the 60-day window. The agency calls them Timely Applicants, and the list is a plain tab-delimited text file with three fields for each entry, the state in the business address, the business activity (dispensary, manufacturer or distributor) and a control number. Company names are not included. The DEA says the file is updated daily and will shrink as applicants are registered, withdraw or lose their state license. Marijuana Moment, which tallied the list on October 30, reported that the DEA had first posted the page on October 28, taken it down after the outlet wrote about it, and restored it the next day.

The tally shows 6,983 timely applicants: 4,197 dispensaries, 2,076 manufacturers and 710 distributors, from at least 43 states plus Washington, D.C. and Puerto Rico. Oklahoma dominates with 2,442 entries, more than a third of the national total, including 1,158 manufacturers, 939 dispensaries and 345 distributors. Florida is second with 812 entries, 748 of them dispensaries, and California third with 771. Maine has 320, Pennsylvania 227, Missouri 209, Arizona 168, Ohio 160, Maryland 142 and Colorado 141. Among the seven states that received the first registrations, Florida’s 748 dispensary applications dwarf the rest: Mississippi lists 97 dispensaries, West Virginia 48, South Dakota 43, Virginia 24, Texas 4 and Alabama 1. Set against the “more than 900” figure in the DOJ release, that suggests the first batch reached a large share of Florida’s applicants and is far from covering the 4,197 dispensaries on the list.

The list serves a practical purpose beyond transparency. From now on, every business in the system is expected to check its trading partners against it.

The November 29 Supply-Chain Rule and Why It Disrupts State Programs

The second document published on October 30 is where the disruption begins. It explains what a Timely Applicant may do while its application is pending, and the short answer is: operate under its state license, but only inside a closed circle. A Timely Applicant can dispense, manufacture or distribute Schedule III medical marijuana with other Timely Applicants and with DEA registrants. A timely distributor can ship to a timely dispensary and buy from a timely manufacturer; a registered dispensary can keep receiving product from a timely distributor. What none of them may do is handle Schedule III medical marijuana with a business that did not file a complete application, with the fee paid, between April 28 and June 26, or that has not applied since, until that business becomes a DEA registrant.

The DEA spells out the consequence. If a Timely Applicant or registrant does business with anyone outside the circle, that conduct could be potential grounds for denying the application or revoking the certificate of registration. The agency expects businesses to confirm the status of every partner and lists the minimum due diligence it has in mind: obtain a copy of the partner’s DEA submission confirmation and verify its document control number (DCN) on the Diversion Control website, obtain a copy of a registrant’s DEA certificate, obtain a copy of the partner’s state license and check that it is active, and keep records of all of it. Registered businesses must also keep the full set of Schedule III records required under 21 CFR part 1304, with a trading partner’s DCN standing in where a DEA registration number would normally go.

Because many businesses will need time to check partners and rearrange supply, the DEA set a transition period. Timely Applicants are expected to complete these checks and establish compliant supply chains no later than November 29, 2026. Inventory already on hand is protected: timely dispensers and distributors may keep possessing, dispensing and distributing Schedule III medical marijuana acquired before October 30, even if it came from a business that is not a Timely Applicant or registrant.

Think of a state medical program as a town where every shop, farm and delivery van has a local permit. The federal rule draws a chalk circle around the ones that also filed federal paperwork by June 26. Inside the circle, trade continues. A shop inside the circle that keeps buying from a farm outside it now risks its own federal application. The farm outside the circle has no federal path at all until it applies and is registered, and the April order’s expedited six-month processing applies only to the spring applicants, so its wait is open-ended. Cannabis Business Times puts the point bluntly: the rule forbids registrants and timely applicants from doing business with non-registered entities, and in states where a meaningful share of licensees never applied, that redraws the supply map in four weeks.

Testing labs get special treatment, and the reason is instructive. Analytical labs are not covered by the regulation that lets Timely Applicants operate before registration, so a lab that is not DEA-registered is, strictly, outside the circle. Yet many states require licensees to send samples to a state-licensed lab, and in some states no lab holds a DEA registration for Schedule III medical marijuana. The DEA says it does not intend to penalize businesses for sending de minimis quantities to a non-registered lab, provided the lab is in the same state and the business keeps detailed records. That discretion applies only when using a DEA-registered lab would violate state law, which the document defines narrowly: either no lab anywhere in the country is DEA-registered for this testing, or state law bars sending samples out of state and no in-state lab is registered. The discretion does not allow a business to receive marijuana back from a non-registered lab.

Two caveats belong here. The document says its contents do not have the force and effect of law and are meant only to clarify existing requirements. And the enforcement risk it describes is administrative, denial or revocation, rather than criminal; the federal prohibition on everyone outside the system is the same one that existed before April.

How States Are Reacting

State regulators were not consulted on the circle, and their programs do not stop at its edge. A state license remains the legal basis for every business in a medical program, registered or not, and state law does not require a federal registration to keep it. In South Dakota, one of the seven first-batch states, Attorney General Marty Jackley issued an opinion that the federal Schedule III listing does not change the state’s medical cannabis program, as Cannabis Business Times reported. That leaves two overlapping rulebooks: a state one that treats all licensees alike, and a federal one that now sorts them into timely applicants, registrants and everyone else.

The DEA’s own list shows how uneven the sorting is. Oklahoma’s 2,442 timely applicants sit in a state with no adult-use market and a very large licensee base, so the share of businesses outside the circle there is a live question. Texas, with 4 timely dispensary applicants, has a small, tightly controlled program. States with dual markets face a different problem: the April order covers only marijuana handled under a state medical license, and the registration form asks each applicant whether it handles recreational marijuana, so a company serving both markets must separate its medical supply chain from everything else. The picture differs sharply from one state to the next, as our state-by-state guide to where weed is legal in the US shows.

DEA Registration Forms for Medical Marijuana Businesses: What Opened in October

The DEA started with the shops. Its portal for state-licensed dispensaries opened on April 29, one day after the federal rule on medical marijuana was published. The rest of the medical supply chain had to wait. In May the agency posted a notice on its website saying that separate applications for medical marijuana manufacturers, growers, analytical labs and distributors would arrive “in the coming weeks,” as Cannabis Business Times reported at the time. The weeks turned into almost five months.

Those applications are now live. According to Cannabis Business Times, the Diversion Control Division opened the new process on October 5 for three groups. A manufacturer, in DEA terms, is any company that cultivates, produces, processes, packages, labels or transfers cannabis, so growers belong here too. A distributor receives and transfers cannabis. An analytical lab tests it. All three use DEA Form 225, the same form number that pharmaceutical manufacturers, distributors and laboratories have long used, now with a medical marijuana track built in.

Dispensaries had their own moment earlier in the year. Those that applied by June 26, within 60 days of the rule, were promised faster handling. That window has closed. A dispensary that still wants to register applies through the same online system, where the DEA now lists a dedicated Form 224M for medical marijuana dispensaries. A business that applies now is not a Timely Applicant: it cannot trade inside the circle until it is actually registered, and it has no promise of six-month processing.

The pool of potential applicants is large. State medical programs serve about 3.9 million registered patients, and every product those patients buy passes through a grower, a processor, a carrier and a lab before it reaches a shelf.

What the New Form 225 Asks and What It Costs

The new version of DEA Form 225 reads like a federal business license application with a few cannabis questions added. Cannabis Business Times quotes two of them directly: “Will your firm be handling medical marijuana?” and “Will your firm be handling recreational marijuana?” Applicants also give their state licensing information and specify what they will work with: marijuana, marijuana extract, or naturally derived delta-9 THC, the main intoxicating compound in the plant, in a product covered by a state medical license or approved by the Food and Drug Administration (FDA).

Then come the background questions. They cover past convictions for controlled substance offenses under state or federal law, any federal controlled substance registration that was surrendered or revoked, and any state professional license or registration that was surrendered or revoked. For a corporation, the same questions apply to officers, partners and stockholders.

The online application has seven steps: business information, email validation, business activity, state licenses, background information, payment and confirmation. The fee is nonrefundable and covers one year. Cannabis Business Times reports $3,699 for manufacturers, $1,850 for distributors and $296 for analytical labs, payable by credit card. The fee reported for dispensaries is $794 a year.

The form also carries a warning that applicants should read slowly. Under federal law, knowingly giving false or fraudulent information on the application can bring up to four years in prison, a fine of up to $250,000, or both.

Why a State-Licensed Business Needs a Federal Registration

The answer goes back to April. Following an executive order that President Trump signed in December, Acting Attorney General Todd Blanche issued an order that moved two things out of Schedule I, the strictest federal category, and into Schedule III: marijuana products approved by the FDA, and marijuana regulated under a state medical cannabis license. The final rule appeared in the Federal Register on April 28 and took effect the same day.

Schedule III substances are legal to handle only for those registered with the DEA. That is the logic behind the forms. A legal analysis by the Congressional Research Service, dated April 30 and cited by Cannabis Business Times, put it plainly: all entities that handle the covered marijuana products, other than end users, will need to register with the DEA in order to do so lawfully.

The rule built a dedicated pathway for state medical licensees to register as manufacturers, distributors or dispensers. It also set a clock: the DEA must make every effort to process applications filed within 60 days of publication within six months, and those early applicants may keep operating under their state license while the application is pending. The October 30 document is the DEA’s reading of that last sentence, and it reads it narrowly: operating while pending means operating with other applicants and registrants, not with the rest of the market.

The rule ties the federal registration tightly to the state one. If a state medical marijuana license is suspended, revoked or expires, the DEA registration is suspended automatically. Manufacturers face an unusual extra step that comes from an international drug treaty: they set a nominal price for their crop, the DEA formally buys it at that price and sells it back, and the crop must sit in a facility the agency can access until that paper transaction is complete.

The money argument for registering is taxes. Section 280E of the tax code bars businesses that traffic in Schedule I or II substances from taking ordinary deductions. The final rule says state licensees will no longer be subject to that bar, while noting that this is not a tax ruling. The Treasury Department and the Internal Revenue Service have since put “Guidance under §280E” on their priority guidance plan for the twelve months from October 1, one of 121 projects on the list. For a sense of the money at stake if marijuana were fully legal, see the Yale Budget Lab’s estimate of a federal marijuana tax.

Insurance is the next test. Under Schedule I, most cannabis operators could buy cover only in the excess and surplus market, at high premiums and on restrictive terms, while large commercial insurers stayed away over anti-money-laundering and banking concerns. Lower tax bills and federal registration make medical operators easier to underwrite, but larger facilities, product liability and recalls, and state rules that do not match FDA standards keep underwriting cautious. The industry expects gradual change over the next year or two, with the first standard (admitted) policies most likely for lower-risk parts of the business.

One limit is clear. Marijuana that is neither in an FDA-approved product nor covered by a state medical license remains in Schedule I. That is why the form asks every applicant whether it handles recreational marijuana, and why companies holding both medical and adult-use licenses are in the least settled position.

What Registration Looks Like in Practice

Filing the form is the start of the process, not the end. The DEA had been visiting dispensaries that applied earlier in the year well before the first certificates were issued. The Mississippi Medical Marijuana Association wrote in August that federal officials carried out on-site inspections at two of the state’s medical cannabis dispensaries in June, and that the operators were told they were among the first businesses in the country to receive such visits. Mississippi is now one of the seven states in the first batch of registrations. Marijuana Moment has reported that the questions DEA officials ask vary between regional offices: a list of 26 questions sent to Colorado businesses in August differed in many places from what Mississippi operators were asked.

The background questions are not a formality either, because a registered business takes on the DEA’s standing rules for everyone who handles controlled substances. One of them, 21 CFR 1301.76(a), says a registrant may not employ, in a role with access to controlled substances, anyone convicted of a felony relating to controlled substances. In an industry where many workers have old drug convictions, that rule has teeth.

A legal analysis from the law firm Bradley describes the first public case. Nicole Huff, CEO of Wildflower Medical Dispensary in Aberdeen, Mississippi, was told that two of her employees fall under the rule. If she keeps them, her choices are to withdraw the application, to give up expedited processing and ask for an employment waiver, or to take the matter to an administrative law judge. In a waiver request the DEA weighs things such as the nature of the old offense, how much access the employee would have to controlled substances, and the safeguards the business has in place. Huff has since told Marijuana Moment that she will take the issue before a DEA judge, and Senator Cory Booker has called the policy “really problematic,” arguing that records for nonviolent offenses involving conduct that is now legal should be expunged.

How Rescheduling Got Here: From an Oval Office Remark to the April Order

The process that produced today’s registration forms began in December 2025. On December 15, asked in the Oval Office about marijuana, President Trump said his administration was “looking at that very strongly,” pointing to the potential for medical research. Three days later, on December 18, he signed an executive order directing Attorney General Pam Bondi to speed up the move of marijuana from Schedule I, the category it shared with heroin and LSD, to Schedule III, alongside drugs such as Tylenol with codeine and anabolic steroids. The order did not legalize recreational marijuana. It pushed agencies to finish a review that had started under the Biden administration.

Reaction split along familiar lines. Veterans groups were among the loudest supporters: Carol Whitmore, national commander of the Veterans of Foreign Wars, said the decision “acknowledges what veterans and their doctors have been saying for years,” and the American Legion argued that Schedule I status had blocked the large trials needed to study cannabis for conditions linked to veteran suicide. Before the signing, a group of House Republicans led by Rep. Pete Sessions and Rep. Andy Harris had urged the President not to proceed, calling marijuana a “harmful drug.” The order also sat awkwardly next to Congress, which in November 2025 voted to ban most intoxicating hemp products from November 2026. Public opinion, meanwhile, has long run ahead of federal law, as our overview of what Americans think about marijuana legalization shows.

The personnel picture shifted too. On January 6 the Senate confirmed Sara Carter as director of the White House Office of National Drug Control Policy by 52 votes to 48, with Sen. Rand Paul breaking with his party to vote against. Carter, the first woman in the post, avoided a firm position on cannabis during her hearings, but on her podcast in 2023 she had described it as a “fantastic way of handling” illnesses such as cancer. Kevin Sabet of Smart Approaches to Marijuana, a prohibitionist group, also welcomed her appointment.

Abroad, the move was read as a signal rather than a settlement. In Jamaica, Delano Seiveright, Minister of State in the Ministry of Industry, Investment and Commerce, said the effect on “banking access, cross-border investment, research collaboration and wider market engagement” would depend on the final details of US implementation.

The April order then turned only part of the executive order into a final rule: medical marijuana under state licenses and FDA-approved products moved to Schedule III, while the question of marijuana as a whole went to the hearing described below.

How the Hearing Began: the DEA’s Case for Schedule III

The registration forms deal with medical marijuana only. The broader question, whether marijuana as a whole belongs in Schedule III, is the subject of the administrative hearing that opened on June 29 in Arlington, Virginia.

The DEA kicked off those highly anticipated hearings with a definitive stance, confirming that the federal government not only proposed but actively supports moving cannabis to Schedule III. The opening statements marked the beginning of what is widely considered the most consequential federal drug reform process in more than half a century.

During the first day of the proceedings, DEA Office of Chief Counsel attorney James J. Schwartz quickly addressed skepticism surrounding the government’s intent. Clarifying that the government is the formal proponent of the rule, originally initiated during the Biden administration and moving forward under a directive from President Donald Trump to expedite the process, Schwartz emphasized that federal attorneys are actively working to prove cannabis has a currently accepted medical use (CAMU).

Under the Controlled Substances Act, proving that cannabis has at least one accepted medical use means it legally can no longer be classified as a Schedule I drug. The government’s argument relies heavily on a 2023 review by the Department of Health and Human Services (HHS), which recognized the therapeutic benefits of cannabis for three specific conditions: anorexia related to a medical condition, chemotherapy-induced nausea, and chronic pain.

The government called its first witness, Dr. Dominic Chiapperino, director of the controlled substance staff at the FDA’s Center for Drug Evaluation and Research. Chiapperino testified that a rigorous 10-month scientific review involving physicians, pharmacologists, and epidemiologists concluded that cannabis’s potential for abuse and dependence is significantly lower than Schedule I and II substances like heroin and fentanyl.

To back the medical relevance of the plant, Chiapperino presented data showing that roughly 60% of cannabis users in states with legal programs still consult healthcare professionals before use, which the government offered as evidence that patients view cannabis as medicine. Furthermore, the FDA’s risk-ratio analysis found that cannabis accounts for fewer overdose deaths than alcohol or prescription opioids, with withdrawal symptoms comparable to tobacco.

Anti-rescheduling advocates present at the hearing attempted to challenge the government’s evaluation methods, arguing against the simplified two-part test used by the HHS to determine medical acceptance. However, Schwartz clarified that the current test is legally binding for the tribunal under a Department of Justice Office of Legal Counsel opinion, effectively blocking opponents from overturning the criteria.

Where the Hearing Stands Now

Testimony wrapped up on July 15 after 11 days of proceedings. The DEA has posted the transcript of every hearing day, more than 2,500 pages in all. Both sides then filed post-hearing briefs, and DEA Chief Administrative Law Judge Derek Julius was left to prepare his recommendation. In its own final brief, the DEA told the judge that more than 30,000 practitioners were treating over six million patients in 43 U.S. jurisdictions, and asked him to recommend the move to Schedule III quickly. That patient figure is the agency’s own and is not directly comparable with the totals that state registries publish.

Then a new document arrived. On September 23 the Government Accountability Office (GAO), the watchdog agency that works for Congress, published a report on the federal drug scheduling process, titled “Drug Scheduling: While DEA Decisions Have Aligned with Recent HHS Recommendations, Both Need Comprehensive Policies.” It found that between 2020 and 2025 the DEA’s decisions matched HHS recommendations for all 84 substances that received a final scheduling decision. It also found that the DEA has no written policies on how its staff are to evaluate and schedule substances, and that the FDA’s procedures have gaps. The GAO made three recommendations, and the agencies agreed with all of them.

Three hearing participants who oppose rescheduling, the National Drug and Alcohol Screening Association, DUID Victim Voices and Dr. Kenneth Finn, asked the judge on September 28 to add the report to the record and allow extra briefing. One day later Julius issued a stay and briefing order that paused the whole matter until the motion was resolved. The government was given until October 13 to respond in no more than 20 pages, and other participants could file responses by the same date.

That pause has now run its course. On October 22 the judge ruled on both pending requests, as described below, and set a short briefing schedule that ends on November 5. None of the orders issued so far sets a date for his recommendation. Whatever he recommends, it is not binding: the final decision rests with DEA Administrator Terrance Cole.

The DEA Marijuana Rescheduling Hearing Dispute, Filing by Filing

What began as a request to add one report to the record grew into a wider argument over whether the hearing should be reopened at all. The sequence below comes from the judge’s orders and from the filings as reported.

On October 9 the government answered the first motion. The DEA said it would leave it to the judge whether the GAO report goes into the record, but it objected to any extra round of written arguments about it, as Marijuana Moment reported at the time. In the agency’s reading, the opponents had mischaracterized the report: it brought no new evidence on the question in front of the judge and pointed to gaps in how the scheduling process is written down, not to flaws in the process itself.

The opponents came back with two new motions on October 12. One asked for permission to reply to the DEA. The other asked the judge, if he admits the report, to reopen the hearing for limited discovery and testimony. On October 13 Smart Approaches to Marijuana (SAM), together with the states of Idaho, Indiana and Nebraska, filed a joint response supporting both the report’s admission and an extra briefing period. No other participant responded.

On October 14 Julius issued an order granting leave to reply and ordering a response to the reopening motion. He accepted the opponents’ reply, said he was reserving his ruling on the GAO report, and gave the government until October 21 to answer the reopening request in no more than ten pages. The case stayed frozen in the meantime.

The DEA met that deadline with a new brief filed on October 21, asking the judge to refuse new discovery and testimony and calling the request an “obvious fishing expedition.” The same day, NDASA, DUID Victim Voices and Dr. Finn asked for, and received, permission to respond to it.

Then, on October 22, the judge decided. In an order reported by Marijuana Moment, Julius granted the motion to admit the GAO report into the record and denied the motion to reopen the hearing. He wrote that some of the subjects the opponents wanted to explore were immaterial for the narrow purpose of the hearing, that others could have been raised when witnesses were on the stand, and that since the GAO is not a party and the report speaks for itself, no further testimony about it was needed. The opponents’ arguments about the report were, he said, their strongest grounds for reopening, and he addressed them with briefs rather than witnesses: the parties may file written arguments limited to two questions, what weight the tribunal should give the report, and whether the gaps in written policy it identified are substantial enough to affect this specific rescheduling proposal. Initial briefs were invited by October 29 and replies by November 5, and the judge said requests for more briefing beyond that are disfavored. The stay remains in place until the briefing closes and then expires on its own terms.

The DEA used its brief to argue that the report does not weaken the rescheduling proposal, as Marijuana Moment reported at the end of October. The opponents’ reply, if filed, will close the record on November 5.

What Discovery Would Have Meant, and Why the Judge Said No

Discovery is the stage of a legal case in which each side can make the other hand over documents and can question witnesses before anyone decides the outcome. Think of it as asking to see the other team’s internal notes before the referee blows the final whistle. In an ordinary lawsuit it is routine. In a DEA rulemaking hearing whose testimony closed in July and whose final briefs are already filed, it was a much bigger ask, and the judge treated it as one.

The opponents presented their request as modest. They wanted to send targeted document requests and take testimony on a short list of subjects: the report itself, the gaps in agency procedure it identified, and why those gaps matter for marijuana. They said the request was in proportion to the issues the report had raised and that they were not trying to reargue the whole case or repeat testimony already given.

The DEA’s answer had several layers. First, it argued that the Administrative Procedure Act (APA), the federal law that sets the rules for how agencies write regulations, does not provide for general discovery or for adding to the record of a rulemaking once testimony has closed. Second, it said a party that wants to supplement the record has to show something specific: that the agency left out unfavorable documents on purpose or through carelessness, that background information is needed to judge whether all relevant factors were considered, or that the agency explained its decision so poorly that a court could not review it. In the DEA’s view, none of that had happened here.

Third, the agency turned the report’s main finding back on the opponents. The GAO found that written policies are missing, the DEA argued, so there is no hidden pile of policy documents to dig up. Fourth, it disputed that the requests were narrow at all, pointing out that they would reach GAO’s materials on every scheduling matter over the previous six years, from every entity GAO contacted, plus the content of every GAO information request. Much of the rest, it said, was already in the record through earlier testimony.

The opponents’ response turned the argument around once more. If the government accepts that no written standard existed, they said, it cannot also claim that the missing standard does not matter.

One way to picture the dispute: an inspector visits a kitchen and finds no written recipe book. The inspector also finds that, over five years, every dish matched the order ticket, just as the DEA’s decisions matched HHS recommendations for all 84 substances the GAO reviewed. The opponents said the missing book could have changed how this particular dish, marijuana, was prepared. The DEA said the marijuana recipe was argued out in full over 11 days of testimony, and that a missing book is not proof that the dish was made wrongly. The judge, in effect, let the inspector’s report into the kitchen file but declined to call the inspector as a witness, and observed that the two sides were closer in their reading of the report than their filings suggested; what divides them is how much the report should matter to this one case.

A Vicente LLP analysis written during the stay noted that under DEA precedent, a party seeking to reopen a closed record after post-hearing briefs must show that the new evidence was not available earlier and that it is material and relevant to the issues in dispute. The GAO report clearly did not exist before September 23. Whether it is material is now the subject of the last round of briefs rather than of new testimony.

What Happens After November 5

Once the reply briefs are in, the stay expires and the matter returns to where it stood in September: a closed record, with one more document in it, waiting for the judge’s recommendation. The judge has not said how long he will take. His recommendation will not settle the question on its own. It goes to the DEA Administrator, and a final rule on marijuana as a whole could itself be challenged in court, as the April order already has been. Lawsuits against that order, brought by state attorneys general, legalization opponents and a cannabis-focused biopharmaceutical company, have been consolidated in the U.S. Court of Appeals for the District of Columbia Circuit, which refused a request to block rescheduling while the litigation goes on.

For businesses, the practical point is that the fight over the hearing does not touch the medical marijuana rule already in force. The stay concerned only the broader question of moving all marijuana to Schedule III. The April order, the registration forms, the first 900 registrations, the November 29 supply-chain deadline and the rule’s statement on Section 280E stay in place unless a court or a later rule changes them. If the broader rescheduling eventually goes through, the circle described above would stop being a circle, because recreational marijuana handled under state law would also fall under Schedule III; until then the circle is the system.

What Is Still Unknown

Several things cannot be answered from the documents available today. The DOJ gave the number of first-round registrations only as “more than 900” and did not break it down by state, so the share of applicants registered in Florida, Mississippi and the other five states is an inference from the DEA’s applicant list, not a published figure. No manufacturer, distributor or lab registration has been announced, and the DOJ has not said when the next batch of dispensary registrations will come. The DEA has not said whether November 29 can move if partners cannot be verified in time, or how it will treat a business whose only in-state supplier is outside the circle. No deadline or expedited window has been announced for the new manufacturer, distributor and lab forms, unlike the 60-day window that dispensaries had.

The timetable for the judge’s recommendation is still open, and so is the question of how much weight he will give the GAO report. What is known about inspections and staffing disputes comes from a state trade association, from press interviews and from lawyers’ commentary, not from DEA guidance, and it concerns a small number of businesses. Tax treatment depends on Treasury guidance that is planned but not yet issued. And Schedule III status, while it lowers some barriers for scientists, does not close the research funding gap.

The fees and form details in this article come from trade press reporting on the DEA application system rather than from a formal agency announcement, so anyone preparing an application should check the current wording in the system itself. The applicant totals come from Marijuana Moment’s count of a DEA file that the agency says changes daily. The account of the October filings relies on the judge’s published orders and on press reports of the briefs; the parties’ full arguments are in the filings themselves.

FAQ

Is marijuana Schedule 3 now?

Partly. Since April 28, marijuana handled under a state medical cannabis license and marijuana in FDA-approved products are in Schedule III of the Controlled Substances Act. Marijuana outside those two categories, including recreational marijuana sold legally under state law, remains in Schedule I. A separate DEA hearing on moving marijuana as a whole to Schedule III finished testimony in July; the judge admitted a Government Accountability Office report to the record on October 22, refused to reopen the hearing for new testimony, and set November 5 as the last day for written arguments. His recommendation has no date, and the DEA Administrator makes the final decision.

How much does DEA registration cost for a medical marijuana business?

According to Cannabis Business Times, the nonrefundable application fee is $3,699 for manufacturers, $1,850 for distributors and $296 for analytical labs, and it covers one year. The fee reported for dispensaries is $794 a year. Fees can change, so the figure shown in the DEA application system at the time of filing is the one that counts.

If marijuana is rescheduled, what happens to businesses that did not apply for DEA registration?

Under the DEA’s October 30 document, businesses that applied between April 28 and June 26 are Timely Applicants and may keep operating with each other and with registered companies while their applications are pending. A business that did not apply in that window has no such authority until it is actually registered, and from November 29 Timely Applicants and registrants are expected not to buy from, sell to or ship through it. A business can still apply now through the DEA’s online system, but it will not have the six-month expedited processing that spring applicants were promised.

Does DEA registration make a state-licensed cannabis business legal under US federal law?

Only within narrow limits. The April order moved marijuana regulated under a state medical cannabis license, and FDA-approved marijuana products, to Schedule III. Recreational marijuana remains in Schedule I at the federal level, even in states that allow it. A DEA registration also depends on the state license: if that license is suspended, revoked or expires, the federal registration is suspended automatically, and trading with a business outside the DEA’s system can be grounds for revoking it. How these rules apply to a specific company is a question for a licensed attorney.

Legal Disclaimer

This article is provided for general information and news purposes only. It is not legal, tax, regulatory or medical advice. Cannabis remains a controlled substance under United States federal law, federal and state rules differ and change frequently, and the registration procedures, fees, deadlines, applicant counts and hearing status described here may have been revised since publication. Businesses and individuals should consult a qualified attorney, tax professional or other licensed adviser in their own jurisdiction before making any decision. The Cannex does not encourage the purchase, cultivation or use of cannabis where it is prohibited by law.

You may also like